Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2025-10-28 Share Issue/Capital Cha…
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 176.3KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice from InhaleRx Ltd regarding the issuance of ordinary shares without disclosure under Part 6D.2 of the Corporations Act 2001 (Cth). It references compliance with sections of the Corporations Act and provides details about the share issuance effective 2 October 2025. The document is short (2347 characters) and serves as a formal announcement of a share issue event rather than a full financial report or detailed analysis. It fits the description of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2025-10-28 English
Application for quotation of securities - IRX 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the number and type of securities to be quoted, issue dates, and related information about the securities issued. It references a previous Appendix 3B announcement about the securities issue. This type of document is a formal announcement related to capital changes, specifically the quotation of newly issued shares. It is not a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, which cover new share issues and related capital structure changes.
2025-10-22 English
Issue of Shares to CEO in Lieu of Accrued Salary Entitlement 2 pages 178.7KB
Transaction in Own Shares Classification · 95% confidence The document is a short announcement regarding the issuance of shares to the CEO in lieu of accrued salary entitlements. It details the number of shares issued, the valuation method, and the rationale behind the issuance. There is no financial report, no detailed financial statements, no regulatory certification, or voting results. The document is an update on a capital transaction involving share issuance but not a full capital change announcement like a stock split or new share issue to the public. It fits best under Transaction in Own Shares (POS) as it reports the company issuing shares to an insider as compensation, which is a form of transaction in own shares. The document length is short (2792 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is POS with high confidence.
2025-10-21 English
Proposed issue of securities - IRX 5 pages 17.2KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a proposed placement or other type of securities issue by Inhalerx Limited. It includes specifics such as the number of securities, issue date, consideration, and compliance with ASX Listing Rules. There is no financial performance data, earnings information, or management discussion. The content focuses solely on the announcement of a new securities issue, which aligns with capital raising or financing activities. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement but a full disclosure of the proposed issue.
2025-10-21 English
HREC Approval to Commence Phase 1 Trial of IRX616a 2 pages 193.9KB
Regulatory Filings Classification · 95% confidence The document is a company announcement about receiving Human Research Ethics Committee (HREC) approval to commence a Phase 1 clinical trial for a drug candidate IRX-616a. It details the study design, funding, and next steps but does not contain any financial data, earnings, or regulatory filings related to financial performance. It is not a report, transcript, or regulatory filing but rather a corporate update on clinical trial progress. This fits best under the category of a general regulatory or corporate announcement that does not fit other specific categories, thus classified as Regulatory Filings (RNS). The document length is about 4992 characters, which is not a brief notice but a detailed announcement, supporting RNS classification rather than a short report publication announcement (RPA).
2025-08-27 English
Half Yearly Report and Accounts 18 pages 1.1MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'InhaleRx Limited Appendix 4D Half-year report' and covers the half-year ended 30 June 2025. It includes detailed financial statements such as the statement of profit or loss, statement of financial position, notes to the financial statements, and directors' report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year, specifically a half-year report. It also references an auditor's review report, which is typical for interim or quarterly reports. The presence of detailed financial statements and management commentary confirms this is a comprehensive interim financial report rather than a brief announcement or a full annual report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2025
2025-08-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.